What is HC Wainwright's Estimate for DBVT FY2029 Earnings?

Key Points

• HC Wainwright cut its FY2029 EPS estimate for DBV Technologies to $0.84 from $1.04 (analyst A. Fein), while the consensus full‑year estimate remains a loss of ($0.82) per share.
• On April 30 DBV missed quarterly expectations, reporting EPS of ($0.56) versus consensus ($0.14) and revenue of $0.90M versus $1.11M, with deeply negative net margin and return on equity.
• Analyst coverage is mixed but positive on average—DBV carries a "Moderate Buy" consensus and an average price target of $40.25, while shares trade near $19.87 (market cap ~$1.11B).

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Equities research analysts at HC Wainwright decreased their FY2029 earnings estimates for shares of DBV Technologies in a research note issued on Friday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $0.84 per share for the year, down from their previous estimate of $1.04. The consensus estimate for DBV Technologies' current full-year earnings is ($0.82) per share.

DBVT has been the subject of a number of other research reports. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research note on Saturday. Citizens Jmp boosted their price target on DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday. Citigroup reissued an "outperform" rating on shares of DBV Technologies in a report on Friday. Finally, Guggenheim restated a "buy" rating and issued a $51.00 price objective on shares of DBV Technologies in a research note on Friday, March 27th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, DBV Technologies presently has an average rating of "Moderate Buy" and an average target price of $40.25.

DBV Technologies Price Performance

Shares of DBVT opened at $19.87 on Monday. The firm has a market capitalization of $1.11 billion, a PE ratio of -4.46 and a beta of -0.96. DBV Technologies has a 1-year low of $7.53 and a 1-year high of $26.18. The company's fifty day moving average price is $20.89 and its 200-day moving average price is $18.89.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.42). The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC grew its position in DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company's stock worth $51,000 after purchasing an additional 744 shares during the period. Truvestments Capital LLC lifted its holdings in shares of DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company's stock valued at $75,000 after buying an additional 1,620 shares during the period. Allworth Financial LP acquired a new position in shares of DBV Technologies in the 4th quarter valued at about $32,000. Royal Bank of Canada purchased a new stake in shares of DBV Technologies in the fourth quarter worth about $34,000. Finally, New York State Common Retirement Fund acquired a new stake in DBV Technologies during the third quarter worth about $34,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.